Print version

pdf Click to download

Search Pub Med

030P London, UK
8th European Workshop on Cannabinoid Research



Effect of the CB1 cannabinoid receptor antagonist AM251 on kissorphin protection against amyloid-β neurotoxicity

N. G. Milton. School of Clinical & Applied Sciences, Leeds Beckett University, Leeds, United Kingdom.

Introduction: Previous in vitro and in vivo studies demonstrate protective properties of kissorphin (KSO) peptides against amyloid-β (Aβ) neurotoxicity1,2. Overexpression of the KiSS-1 gene, that encodes the KSO peptides, is also neuroprotective1,3. Endocannabinoids and KSO peptides are neuroprotective against Aβ 25-35, but not Aβ 31-35 peptides1,4. The KiSS-1 gene expression is regulated by endocannabinoids5. The aim of this study was to determine whether endocannabinoids contribute to KSO protection against Aβ toxicity using a CB1 cannabinoid receptor antagonist.

Method: This study employed MTT cell viability assays to investigate the effects of the CB1 antagonist AM281 on KSO 1-6 protection against Aβ 25-35 neurotoxicity in human neuroblastoma SH-SY5Y cells. The effects of AM281 on Aβ 25-35 induced neurotoxicity in KiSS-1 gene overexpressing SH-SY5Y cells (PKiSS)1,3 was also investigated1,3. Data was analyzed by one-way analysis of variance (ANOVA).

Results: The CB1 antagonist AM281 (0.01-10μM) promoted a concentration dependent increase in 10μM Aβ 25-35 induced neurotoxicity in SH-SY5Y cells in the presence of 10μM KSO 1-6 (Figure 1A). The PKiSS protection against 10μM Aβ 25-35 was reversed by the CB1 antagonist AM281 (10μM) and anti-KSO antibody (1μg/ml). In the presence of anti-KSO antibody 10μM 2-AG was protective against 10μM Aβ 25-35.


Figure 1. (A) Dose-response curves for AM281 in the presence of 10μM Aβ 25-35 with or without 10μM KSO 1-6, on MTT reduction in SH-SY5Y cells. (B) PKiSS SH-SY5Y cells were exposed to 10μM Aβ 25-35 alone; 10μM Aβ 25-35 plus 10μM AM281; 10μM Aβ 25-35 plus 1μg/ml anti-KSO antibody; 10μM Aβ 25-35 plus 1μg/ml control antibody; 10μM Aβ 25-35 plus 1μg/ml anti-KSO antibody with 10μM 2-AG; 10μM Aβ 25-35 plus 1μg/ml control antibody with 10μM 2-AG; and cell viability determined by MTT reduction. Results are mean ± SEM (n=8 for each data point); * = P< 0.05 vs Aβ 25-35 alone (one-way ANOVA).

Conclusion: In conclusion, protection against Aβ 25-35 induced neurotoxicity by KSO and KiSS-1 overexpression in SH-SY5Y cells is reversed by the AM281 CB1 antagonist. Anti-KSO antibodies prevent neuroprotection by KiSS-1 overexpression and 2-AG restores neuroprotection. This suggests KSO neuroprotection against Aβ involves activation of endocannabinoids.


(1) Milton NGN et al. (2012). ACS Chem Neurosci 3: 706-719.

(2) Jiang JH et al. (2015). Neurobiol Learn Mem123: 187-95.

(3) Chilumuri A & Milton NGN (2013). ISRN Neuroscience 2013: 253210.

(4) Milton NGN (2002). Neurosci Letts 332: 127-130.

(5) Karamikheirabad M et al. (2013). Clin Exp Reprod Med 40: 155-162.